Huimin Zhang*†, Yuhui Pang†, Chuanbao Ma†, Jianying Li†, Huaquan Wang*, Zonghong Shao*
Oncology Research, Vol.26, No.3, pp. 421-429, 2018, DOI:10.3727/096504017X15049221237147
Abstract Resistance to bortezomib (BZ) is the major problem that largely limits its clinical application in multiple
myeloma treatment. In the current study, we investigated whether ClC5, a member of the chloride channel
family, is involved in this process. The MTT assay showed that BZ treatment decreased cell viability in three
multiple myeloma cell lines (ARH77, U266, and SKO-007), with IC50 values of 2.83, 4.37, and 1.91 nM,
respectively. Moreover, BZ increased the conversion of LC3B-I to LC3B-II and expressions of beclin-1
and ATG5, concomitantly with a decreased p62 expression. Pharmacological inhibition of autophagy with
3-MA… More >
Login
Register
